UNSPSC 51142642: Flurothyl

This classification denotes a cns stimulant with the molecular formula C4H4F6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Z467FG2YK, chemically known as 2,2,2-trifluoroethyl ether but generally known as flurothyl, which bears US NIH Compound Identifier 9528. European Medicines Agency schedules Flurotyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07750MIG. The term FLUROTYL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17).

As of Q4 2014, FLUROTHYL remains the US FDA Preferred Term for this commodity. Flurothyl bears US NLM identifiers UMLS ID C0016380 and NCI Concept Code C76624. SMILES: C(C(F)(F)F)OCC(F)(F)F.

UNSPSC 51142642 Flurothyl is a Commodity code that encompasses pharmaceutical and medical products procured by state and local health agencies, though recent solicitations tagged under this code show minimal direct activity for flurothyl itself and instead reflect broader state and local pharmaceutical procurement spanning naloxone, generic multi-source drugs, OTC products, and direct-to-manufacturer prescription programs. State and local governments use this code tier to solicit pharmaceutical inventory—emergency response medications, generic formulary products, and specialized therapeutics—typically through county health departments, state health and human services commissions, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Issuing bodies include county health systems (such as Seminole County, Florida), state-level HHS agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other member states). The procurement mix ranges from tactical, single-commodity buys—emergency naloxone and drug deactivation systems—to large-scale formulary contracts spanning hundreds of generic pharmaceuticals with complex pricing and wholesaler routing requirements.

Recent opportunities show geographic concentration in Florida and Texas, with multistate cooperative purchasing extending into the Upper Midwest and Pacific Northwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels—an exploratory procurement intended to inform future RFP development. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026 (response due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), requiring cGMP and Drug Supply Chain Security Act compliance, with contract effectiveness July 1, 2026. The code shows active procurement but limited direct flurothyl demand; vendors should assess whether state and local pharmaceutical portfolios include flurothyl-containing products or position under broader generic pharmaceutical or OTC agreements.